http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Immunogenicity and Efficacy of Schmallenberg Virus Envelope Glycoprotein Subunit Vaccines
Abaineh D. Endalew,Bonto Faburay,Jessie D. Trujillo,Natasha N. Gaudreault,A. Sally Davis,Vinay Shivanna,Sun-Young Sunwoo,Wenjun Ma,Barbara S. Drolet,D. Scott McVey,Igor Morozov,William C. Wilson,Juerg 대한수의학회 2019 Journal of Veterinary Science Vol.20 No.6
The Schmallenberg virus (SBV) is an orthobunyavirus that causes abortions, stillbirths, and congenital defects in pregnant sheep and cattle. Inactivated or live attenuated vaccines have been developed in endemic countries, but there is still interest in the development of SBV vaccines that would allow a differentiationng of infected from vaccinated animals (DIVA). Therefore, an attempt was made to develop novel DIVA-compatible SBV vaccines using SBV glycoproteins expressed in baculovirus. All vaccines and phosphate buffered saline (PBS) controls were prepared with adjuvant and administered subcutaneously to cattle at six6 months (Ed note: Numerals 1 to 9 are written in words.)of age. The first trial included two2 groups of animals vaccinated with either carboxyl-terminus glycoprotein (Gc) or PBS and boosted after two2 weeks. In the second trial, three3 groups of cattle were administered either Gc, Gc and Gnamino-terminus glycoprotein, or PBS with a booster vaccination after three3 weeks. The animals were challenged with the SBV nine9 days after the booster vaccination in the first study, and three3 weeks after the booster vaccination in the second study. Using SBV Gc-specific ELISAenzyme-linked immunosorbent assay, antibodies were first detected in serum samples 14 days after the first vaccination in both trials, and peaked on days seven7 and nine9 after the booster in the first and second trials, respectively. Low titers of neutralizing antibodies were detected in serum from only 3/6 and 2/4 animals in the first and second trial, respectively, at 14 days after the first vaccination. The titers increased 2 to 3-fold after the booster vaccination. On the other hand, SBV-specific RNA was detected in the serum and selective tissues in all animals after the challenge. The SBV candidate vaccines neither prevented viremia nor conferred protection against the SBV infection.